Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Shree Ganesh Biotech (India)BOM:539470 +4.08%44 Cyclically Adjusted PS Ratio is 0.37 as of Sep. 07, 2026, which is 30% below its 10-year median of 0.53. GuruFocus rates BOM:539470 with a GF Score™ of 44/100 and a GF Value™ of ₹0.25 (Significantly Overvalued). The stock has 2 warning signs investors should review. Among 199 Agriculture companies, Shree Ganesh Biotech (India) ranks better than 80.4% on this metric.
The historical rank and industry rank for Shree Ganesh Biotech (India)'s Cyclically Adjusted PS Ratio or its related term are showing as below:
BOM:539470'
s Cyclically Adjusted PS Ratio Range Over the Past 10 Years
Min: 0.36 Med: 0.53 Max: 0.81
Current: 0.36
During the past years, Shree Ganesh Biotech (India)'s highest Cyclically Adjusted PS Ratio was 0.81. The lowest was 0.36. And the median was 0.53.
BOM:539470's Cyclically Adjusted PS Ratio is ranked better than 80.4% of 199
companies
in the Agriculture industry
Industry Median: 1.02
vs BOM:539470: 0.36
The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.
Shree Ganesh Biotech (India)'s adjusted revenue per share data for the three months ended in Jun. 2026 was ₹0.036. Add all the adjusted revenue per share for the past 10 years together and divide 10 will get our Cyclically Adjusted Revenue per Share, which is ₹1.38 for the trailing ten years ended in Jun. 2026.
Shiller PE for Stocks: The True Measure of Stock Valuation
Shree Ganesh Biotech (India) (BOM:539470) Cyclically Adjusted PS Ratio Explanation
Compared with the regular PS Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PS Ratio smoothed out the fluctuations of revenue during business cycles. Therefore it is more accurate in reflecting the valuation of the company.
If a company has consistent business performance, the Cyclically Adjusted PS Ratio should give similar results to regular PS Ratio.
Shree Ganesh Biotech (India) Cyclically Adjusted PS Ratio Related Terms
Shree Ganesh Biotech (India) Cyclically Adjusted PS Ratio Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Shree Ganesh Biotech (India) Cyclically Adjusted PS Ratio Chart
BOM:539470 vs CTVA, CF, MOS: Cyclically Adjusted PS Ratio Comparison
For the Agricultural Inputs subindustry, Shree Ganesh Biotech (India)'s Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Shree Ganesh Biotech (India) Cyclically Adjusted PS Ratio vs Agriculture Industry
For the Agriculture industry and Basic Materials sector, Shree Ganesh Biotech (India)'s Cyclically Adjusted PS Ratio distribution charts can be found below:
* The bar in red indicates where Shree Ganesh Biotech (India)'s Cyclically Adjusted PS Ratio falls into.
Shree Ganesh Biotech (India) Cyclically Adjusted PS Ratio Calculation
Like the Shiller PE Ratio, the Cyclically Adjusted PS Ratio takes the Revenue per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/S calculation. Because it considers this 10-year average, it's often referred to as the CAPS Ratio.
The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.
What does a Cyclically Adjusted PS Ratio of 0.37 mean?
Shree Ganesh Biotech (India) (BOM:539470) has a Cyclically Adjusted PS Ratio of 0.37 as of Sep. 07, 2026. Cyclically Adjusted PS Ratio is the ratio of share price to a company's inflation-adjusted revenue per share over a 10-year period. View historical data on Shree Ganesh Biotech (India) and its competitors. This is 30% below median its historical median of 0.53. Over the past decade, Shree Ganesh Biotech (India)'s Cyclically Adjusted PS Ratio has ranged from 0.36 to 0.81. According to the industry distribution chart, Shree Ganesh Biotech (India) ranks #39 out of 199 companies in the Agriculture industry, placing it in the top 19.6%.
Is Shree Ganesh Biotech (India)'s Cyclically Adjusted PS Ratio too high?
Shree Ganesh Biotech (India)'s current Cyclically Adjusted PS Ratio of 0.37 is 30% below median its 10-year median of 0.53. Over the past 10 years, this metric has ranged from a low of 0.36 to a high of 0.81. The Agriculture industry median Cyclically Adjusted PS Ratio is 1.02. Shree Ganesh Biotech (India)'s value of 0.37 is 63.7% below this industry median. Based on the distribution chart, Shree Ganesh Biotech (India) ranks #39 out of 199 companies in the Agriculture industry, which is in the top quartile — a strong position relative to peers. Overall, Shree Ganesh Biotech (India) has a GF Score™ of 44/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Shree Ganesh Biotech (India)'s Cyclically Adjusted PS Ratio compare to CTVA and CF?
According to the Agriculture industry distribution chart, Shree Ganesh Biotech (India) ranks #39 out of 199 companies for Cyclically Adjusted PS Ratio. This places Shree Ganesh Biotech (India) in the top 20% of its industry — outperforming the majority of peers. The industry median Cyclically Adjusted PS Ratio is 1.02. Shree Ganesh Biotech (India)'s value of 0.37 is 63.7% below this benchmark. Historically, Shree Ganesh Biotech (India)'s own Cyclically Adjusted PS Ratio has ranged from 0.36 to 0.81 over the past decade. While the company's 10-year median is 0.53 vs. the industry median of 1.02, Shree Ganesh Biotech (India) has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted PS Ratio for an Agriculture company?
The median Cyclically Adjusted PS Ratio among Agriculture companies is 1.02, based on 199 companies in the industry. Companies in the top quartile (top 25%) have a Cyclically Adjusted PS Ratio significantly above this median, while those in the bottom quartile fall well below. However, Cyclically Adjusted PS Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Shree Ganesh Biotech (India)'s current Cyclically Adjusted PS Ratio of 0.37 is 63.7% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted PS Ratio mean?
A high Cyclically Adjusted PS Ratio can signal that a stock is expensive relative to its fundamentals. Cyclically Adjusted PS Ratio is the ratio of share price to a company's inflation-adjusted revenue per share over a 10-year period. View historical data on Shree Ganesh Biotech (India) and its competitors. For the Agriculture industry, the median Cyclically Adjusted PS Ratio is 1.02 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Shree Ganesh Biotech (India)'s current Cyclically Adjusted PS Ratio is 0.37, which is 30% below median its own 10-year median of 0.53. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Shree Ganesh Biotech (India) stock overvalued right now?
Based on GuruFocus' analysis, Shree Ganesh Biotech (India) (BOM:539470) is currently considered Significantly Overvalued. The stock's GF Value™ is ₹0.25, compared to a current price of ₹0.51 — trading 104% above its estimated fair value. The current Cyclically Adjusted PS Ratio is 0.37, which is 30% below median its 10-year median of 0.53 and 63.7% below the Agriculture industry median of 1.02. Shree Ganesh Biotech (India)'s overall GF Score™ is 44/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted PS Ratio calculated?
Cyclically Adjusted PS Ratio is calculated from a company's financial statements. For Shree Ganesh Biotech (India) (BOM:539470), the current Cyclically Adjusted PS Ratio is 0.37 as of Sep. 07, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Shree Ganesh Biotech (India) (BOM:539470) Overvalued in 2026?
Based on GuruFocus' analysis, Shree Ganesh Biotech (India) stock appears to be overvalued.
The current stock price of ₹0.51 is trading 104% above its estimated GF Value™ of ₹0.25.
GuruFocus considers Shree Ganesh Biotech (India) to be Significantly Overvalued.
Key valuation signals for BOM:539470:
Cyclically Adjusted PS Ratio: 0.37 (30% below median its 10-year median of 0.53)
GF Value™: ₹0.25 vs. price of ₹0.51 (104% above fair value)
Industry Position: 63.7% below the Agriculture median (#39 of 199)
No single metric tells the full story. See the BOM:539470 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Shree Ganesh Biotech (India) Ltd is an India-based company mainly engaged in the business of production, processing and marketing of high-quality hybrid seeds for different crops like corn, sunflower, cotton, paddy, grain sorghum, etc.
44GF Score
Get the complete analysis for BOM:539470
Cyclically Adjusted PS Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOM:539470 has been successfully added to your 
